Picture of Vaxart logo

VXRT — Vaxart News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapTurnaround

Vaxart Inc expected to post a loss of 14 cents a share - Earnings Preview

* Vaxart Inc  VXRT.OQ   VXRT.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 2 (estimated)
for the period ending March 31 2024
    * The South San Francisco California-based  company is
expected to
report a 18.5% increase in revenue to $800 thousand from $675
thousand a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Vaxart Inc is for a loss
of 14
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 12.1%
in the last three months. ​
    * Wall Street's median 12-month price target for Vaxart Inc
is
$5.00​, above​ its last closing price of $0.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.16       -0.14      -0.12     Beat    17.2
 Sep. 30 2023  -0.18       -0.18      -0.11     Beat    37.7
 Jun. 30 2023  -0.18       -0.18      -0.16     Beat    11.1​
 Mar. 31 2023  -0.18       -0.19      -0.19     Met     -1.8
 ​​Dec.        -0.22       -0.23      -0.18     Beat    20.9
 31 2022                                                
 Sep. 30 2022  -0.25       -0.24      -0.23     Beat    5.2​
 Jun. 30 2022  -0.22       -0.21      -0.23     Missed  -9.5
 Mar. 31 2022  -0.16       -0.16      -0.20     Missed  -23.1
 This summary was machine generated April 30 at 11:42 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Vaxart

See all news